Covid-19

The eighth eBook of the Hamilton series is now available to download for free. In ‘Assessing the Efficacy of Vaccines through Laboratory Assays‘, the authors discuss the key milestones achieved throughout the history of vaccine development, the laboratory tests commonly used to assess vaccines’ efficacy, and we describe how the latter can be automated using […]

In the eighth eBook of the Hamilton series, ‘Assessing the Efficacy of Vaccines through Laboratory Assays’, we discuss: Vaccine development: Key milestones and impact of Covid-19 Laboratory tests commonly used to assess vaccines’ efficacy and the benefits of automating them Hamilton standardised and customised solutions for workflows such as qPCR, NGS, ELISA/ELISpot and virus-neutralisation assays

The University of Queensland’s re-engineered clamp platform has produced a vaccine that is equally safe and virus-neutralising as an approved Covid vaccine considered among the best in its class. The pivotal proof-of-concept testing clears the way to progress the Clamp2 technology in a range of research programmes.   Project leader, Associate Professor Keith Chappell, said the […]

Patrick Speedie, Co-Founder & Co-CEO of IN-PART, explores why a global approach is needed for the best science to prosper and the lessons industry can take from the Covid-19 pandemic.    The Covid-19 pandemic unequivocally demonstrated the power of industry-academia collaboration, with the fastest ever development, testing and approval of a life-saving vaccine. We saw colleagues […]

This is the latest episode of the free DDW narrated podcast, “Drug discovery trends: From regulation to embracing AI”, which covers two articles written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: From the Editor: Law and order and How AI in pharma can live up to the hype. In […]

DDW’s Megan Thomas looks at how different diseases will benefit from the success of therapeutic antibodies. Cancer Monoclonal antibodies (mAbs) are a type of targeted drug therapy, and as such are often used to treat cancer. Alongside surgery, radiation and chemotherapy, antibody-based immunotherapy is considered to be a main component of cancer therapy1. This is […]

Researchers from Korea conducted a clinical trial to assess the immunogenicity and safety of GBP510/AS03 relative to the ChAdOx1-S vaccine. The interim results show that GBP510/AS03 had an acceptable safety profile and induced stronger antibody responses when compared with ChAdOx1-S GBP510 is a recombinant vaccine adjuvanted with AS03, designed to target the SARS-CoV-2 virus’s spike […]

GeNeuro and Verily will work together to investigate biomarkers related to activation of the proinflammatory HERV-W envelope protein (W-ENV) in SARS-CoV-2 infection. Through this collaboration, the companies will build on results published earlier this year, which evidenced the in vitro activation of HERV-W by SARS-CoV-2 in susceptible individuals and the correlation between W-ENV protein levels […]

A UK-based study will investigate whether a common anti-viral medication could double up as a treatment for long Covid. The project involves teams from the University Hospitals of Derby and Burton NHS Foundation Trust and the University of Exeter, in collaboration with Gilead Sciences. Globally, estimates suggest that over 144 million people developed long Covid, […]

The UK’s University of Oxford is taking the lead on two collaborative international projects to improve the response to new Covid-19 variants and contribute to future pandemic preparedness. Researchers at Harvard Medical School (HMS) in the US and the University of Oxford have developed a new artificial intelligence (AI) tool named EVEscape that can predict […]

According to the National Institutes for Health, some form of long Covid affects around 10% of people infected with Covid-19, with fatigue being the most common symptom. Despite the size of the market and the global impact, there are currently no effective treatments. Diana Spencer caught up with Bill Hinshaw, President & CEO of Axcella […]

Novavax has become the next company to have an updated version of its Covid-19 vaccine approved in the US. The Food and Drug Administration (FDA) amended the emergency use authorisation (EUA) of the Novavax Covid-19 Vaccine, Adjuvanted, for use in individuals 12 years of age and older to include the 2023-2024 formula. Individuals 12 years […]

Researchers have uncovered a link between antiviral drug molnupiravir and a pattern of mutations in the SARS-CoV-2 virus. Molnupiravir induces mutations in the virus’s genome during replication, with the aim of damaging or killing the virus. It was one of the first antivirals available on the market during the Covid-19 pandemic and was widely adopted […]

Hosted by DDW and sponsored by Azenta, ‘What are some of the biggest challenges related to the delivery of RNA therapeutics?’ will be free to attend on 27 September at 7am PST | 10am ET | 3PM BST | 4PM CET. Join this free roundtable to learn about challenges related to the delivery of RNA […]

The EU has historically been a leader in vaccine research, development and manufacturing, but is now seeing a decline in vaccine research, according to data published by Vaccines Europe (VE). The EU has hosted approximately 20% of global vaccine clinical trials over the past two decades, as well as research facilities affiliated with the world’s […]

ICON, a healthcare intelligence and clinical research organisation, with the US Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response within the US Department of Health and Human Services, will execute a clinical trial to evaluate the effectiveness of next-generation Covid-19 vaccine candidates. Next generation Covid-19 vaccines could […]